Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas
  
Teva logo outside building
Teva reported strong Phase IIb data for its anti-TL1A agent in IBD indications • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Therapy Areas